# A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

> **NCT06738251** · PHASE3 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 402 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** SHR-A2102 for Injection
- **DRUG:** Docetaxel Injection
- **DRUG:** Paclitaxel Injection
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Pemetrexed Disodium for Injection

## Key facts

- **NCT ID:** NCT06738251
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-12
- **Primary completion:** 2026-07
- **Final completion:** 2027-09
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06738251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06738251, "A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06738251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*